海昇药业
(870656)
| 流通市值：4.66亿 | | | 总市值：18.64亿 |
| 流通股本：2500.01万 | | | 总股本：1.00亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 369,056,014.58 | 446,853,145.51 | 186,341,856.34 | 314,755,697.46 |
| 应收票据及应收账款 | 17,248,190.75 | 18,559,556.78 | 20,631,299.26 | 17,009,978.65 |
| 其中：应收票据 | - | - | - | 338,059.81 |
| 应收账款 | 17,248,190.75 | 18,559,556.78 | 20,631,299.26 | 16,671,918.84 |
| 应收款项融资 | 12,311,351.22 | 9,153,560.26 | 13,134,020.7 | 4,119,262.93 |
| 预付款项 | 2,053,386.99 | 1,755,339.69 | 2,225,540.75 | 1,247,380.69 |
| 其他应收款合计 | 264,624.59 | 285,130.66 | 303,007.73 | 282,519.94 |
| 存货 | 29,281,152.04 | 24,398,125.27 | 27,051,865.27 | 33,954,257.79 |
| 其他流动资产 | 3,688,312.05 | 4,513,567.42 | 2,568,375.98 | 3,727,780.23 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 503,903,032.22 | 505,518,425.59 | 508,255,966.03 | 505,096,877.69 |
| 非流动资产: | | | | |
| 固定资产 | 130,745,880.79 | 126,196,141.57 | 70,900,342.13 | 72,076,863.93 |
| 在建工程 | 43,191,569.82 | 46,416,971.95 | 56,713,845.91 | 44,569,219.66 |
| 无形资产 | 22,333,499.34 | 22,540,723.5 | 23,541,653.04 | 23,635,204.18 |
| 开发支出 | - | - | 886,158.14 | 102,720.78 |
| 长期待摊费用 | 284,233.44 | 328,345.95 | 519,247.45 | 416,570.97 |
| 递延所得税资产 | 234,993.59 | 249,240 | 207,305.58 | 175,561.89 |
| 其他非流动资产 | 3,033,136.98 | 1,962,118.86 | 12,905,957.39 | 16,528,525.29 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 199,823,313.96 | 197,693,541.83 | 165,674,509.64 | 157,504,666.7 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 703,726,346.18 | 703,211,967.42 | 673,930,475.67 | 662,601,544.39 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 12,025,870.63 | 22,186,862.02 | 13,659,886.81 | 13,380,868.94 |
| 其中：应付票据 | - | 696,883.4 | 3,855,372.23 | 5,963,780.44 |
| 应付账款 | 12,025,870.63 | 21,489,978.62 | 9,804,514.58 | 7,417,088.5 |
| 合同负债 | 323,957.97 | 1,650,162.68 | 641,310.94 | 232,815.36 |
| 应交税费 | 2,979,135.8 | 4,355,174.31 | 2,253,755.78 | 1,741,582.06 |
| 其他应付款合计 | 21,827,376.52 | 21,873,258.4 | 21,701,336.6 | 21,799,685.07 |
| 其他流动负债 | 61,583.95 | 154,542.62 | 102,174.09 | 63,027.06 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 37,217,924.87 | 50,220,000.03 | 38,358,464.22 | 37,217,978.49 |
| 非流动负债: | | | | |
| 递延收益 | 274,074.2 | 351,597.84 | 429,121.48 | 506,645.12 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 274,074.2 | 351,597.84 | 429,121.48 | 506,645.12 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 37,491,999.07 | 50,571,597.87 | 38,787,585.7 | 37,724,623.61 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 80,000,000 | 80,000,000 | 80,000,000 | 80,000,000 |
| 资本公积 | 344,827,551.37 | 344,490,549.04 | 344,418,713.16 | 344,033,071.34 |
| 专项储备 | 853.97 | 4,782.59 | - | - |
| 盈余公积 | 41,426,934.4 | 41,426,934.4 | 36,351,912.06 | 36,351,912.06 |
| 未分配利润 | 199,979,007.37 | 186,718,103.52 | 174,372,264.75 | 164,491,937.38 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 666,234,347.11 | 652,640,369.55 | 635,142,889.97 | 624,876,920.78 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 666,234,347.11 | 652,640,369.55 | 635,142,889.97 | 624,876,920.78 |
| 负债和股东权益合计 | 703,726,346.18 | 703,211,967.42 | 673,930,475.67 | 662,601,544.39 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-29 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |